Condition: Cannabis · THC · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
The purposes of this study are 1) to determine if CBD modulates THC-induced acute psychoactive effects at different CBD:THC ratios, compared with the control product (0:20, 20:20, 40:20, 80:20, 120:20) and 2) to determine if different doses of CBD modulate other THC induced behavioral effects, compared with the control product and 3)To explore qualitatively whether CBD modulates THC effects by mechanisms that are not detected with standard clinical research tools.
This description comes directly from the study's public registry record.
Pamela Lachance, PhD · 514-890-8000 · pamela.lachance-touchette.chum@ssss.gouv.qc.ca
François-Olivier Hébert, PhD · 581 741-4941 · francois-olivier.hebert.chum@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Centre de recherche du Centre Hospitalier Universitaire de Montréal | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06099379